- Asimov and AGC Biologics have signed a licensing agreement for Asimov’s LV Edge Packaging cell line at AGC Biologics’ Milan facility.
- The agreement enables lentiviral vector production using a single-plasmid transfection approach for cell and gene therapy programmes.
Asimov has signed a licensing agreement with AGC Biologics for its off-the-shelf LV Edge Packaging cell line. Under the agreement, AGC Biologics’ Cell and Gene Center of Excellence in Milan will offer a lentiviral packaging system that uses a single-plasmid transfection, replacing the standard four-plasmid process.
The agreement covers the deployment of the LV Edge Packaging System at the Milan site, enabling lentiviral vector production for cell and gene therapy developers. According to the companies, the system is designed to support more consistent manufacturing by reducing the variables associated with traditional four-plasmid transfection methods. The arrangement expands AGC Biologics’ contract manufacturing and CDMO services in the cell and gene therapy space.
Asimov stated that the LV Edge Packaging System combines an engineered HEK293 cell line with inducible viral genes, software for transfer plasmid design, and ready-to-transfer manufacturing processes. The system is intended to reduce GMP plasmid costs, process complexity, and supply chain risk, while achieving harvest titres exceeding those seen with traditional transient transfection across multiple therapeutic transgenes.
“We are thrilled to be partnering with AGC Biologics, a leader in cell and gene therapy manufacturing, to expand access to our high performance lentiviral production system.”
Alec Nielsen, co-founder and CEO of Asimov
AGC Biologics said its Milan site has evaluated the LV Edge Packaging system using clinically relevant genes of interest and will now make the technology available to customers globally.
